DWA
CNCE

Delos Wealth Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Delos Wealth Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-33
Closed -$193 – 420
2022
Q4 		$193 Buy
+33
New +$174 ﹤0.01% 372

Delos Wealth Advisors's CNCE Position: Q1 2023 in Review

Delos Wealth Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 33 shares — an estimated $193 sold.

Delos Wealth Advisors first reported a position in CNCE in Q4 2022 and held it in 1 quarter. The position peaked at $193 in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

  • Delos Wealth Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Delos Wealth Advisors sold 33 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $193.
  • Delos Wealth Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
  • Delos Wealth Advisors's Concert Pharmaceuticals, Inc. position peaked at $193 in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on Delos Wealth Advisors's 13F filing for Q1 2023, filed 15 May 2023.